Research Analysts Offer Predictions for Biogen Q1 Earnings

Biogen Inc. (NASDAQ:BIIB) – Zacks Research cut their Q1 2026 earnings per share estimates for shares of Biogen in a report issued on Wednesday, March 12th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings per share of $3.49 for the quarter, down from their previous forecast of $3.59. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Zacks Research also issued estimates for Biogen’s Q2 2026 earnings at $4.30 EPS, Q3 2026 earnings at $4.07 EPS, Q4 2026 earnings at $4.09 EPS, FY2026 earnings at $15.96 EPS and FY2027 earnings at $16.84 EPS.

Other research analysts also recently issued reports about the company. Truist Financial reduced their price objective on Biogen from $220.00 to $210.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Bank Of America (Bofa) cut their price target on Biogen from $178.00 to $163.00 and set a “neutral” rating on the stock in a report on Tuesday, February 11th. StockNews.com downgraded Biogen from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 28th. Piper Sandler reiterated a “neutral” rating and issued a $135.00 price target (down from $138.00) on shares of Biogen in a report on Tuesday, February 18th. Finally, Morgan Stanley cut their price target on Biogen from $192.00 to $157.00 and set an “equal weight” rating on the stock in a report on Thursday, February 13th. Seventeen equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, Biogen currently has a consensus rating of “Hold” and a consensus target price of $213.33.

Biogen Trading Down 0.4 %

BIIB opened at $139.44 on Friday. The stock’s fifty day moving average is $143.09 and its two-hundred day moving average is $164.30. The company has a market capitalization of $20.41 billion, a P/E ratio of 12.46, a PEG ratio of 1.51 and a beta of 0.01. Biogen has a 52 week low of $128.51 and a 52 week high of $238.00. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.27.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%.

Insiders Place Their Bets

In other Biogen news, Director Stephen A. Sherwin sold 8,760 shares of Biogen stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the sale, the director now owns 11,318 shares of the company’s stock, valued at approximately $1,697,926.36. The trade was a 43.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by insiders.

Institutional Trading of Biogen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BIIB. Lansforsakringar Fondforvaltning AB publ purchased a new position in shares of Biogen during the 4th quarter valued at about $7,380,000. PKO Investment Management Joint Stock Co purchased a new position in shares of Biogen during the 4th quarter valued at about $1,193,000. Wealthedge Investment Advisors LLC purchased a new position in shares of Biogen during the 4th quarter valued at about $265,000. Lighthouse Financial LLC purchased a new position in shares of Biogen during the 4th quarter valued at about $321,000. Finally, Siemens Fonds Invest GmbH raised its stake in shares of Biogen by 159.4% during the 4th quarter. Siemens Fonds Invest GmbH now owns 14,321 shares of the biotechnology company’s stock valued at $2,190,000 after buying an additional 8,801 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.